跳至主要内容
临床试验/NCT01233544
NCT01233544终止3 期

The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial

University of Aarhus4 个研究点 分布在 2 个国家目标入组 300 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
3 期
状态
终止
入组人数
300
试验地点
4
主要终点
Local progression-free survival

研究概览

简要总结

This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases.

Primary end point is local progression free survival.

详细描述

Patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either RFA or SBRT. Primary end point i local progression free survival. Chemotherapy is allowed before and after study treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adenocarcinoma of the colon or rectum
  • Liver metastases
  • Inoperable (technical or medical)
  • 1-4 metastases
  • Maximum 40 mm in diameter
  • Suitable for both therapies, RFA and SBRT

排除标准

  • Uncontrolled extrahepatic disease and uncontrolled primary cancer
  • Liver cirrhosis

结局指标

主要结局

Local progression-free survival

时间窗: 3 years

次要结局

  • Survival(3 years)
  • Progression (local or distant)(3 years)
  • Toxicity(3 years)
  • Quality of life(3 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Radiofrequency Ablation Versus Stereotactic... | 临床试验